Drug-Induced Hypothyroidism during anti-tuberculosis treatment of multidrug-resistant tuberculosis: Notes from the field
Open accessAbstract
We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during anti-tuberculosis treatment; the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on anti-retroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In MDR-TB patients receiving anti-TB, one-fourth developed primary hypothyroidism: 32% in patients who received a regimen containing ethionamide, 35% in those with para-aminosalicylic acid, and 44% in HIV-positive patients on antiretroviral therapy.
“In MDR-TB patients receiving anti-TB, one-fourth developed PH: 32% in patients who received a regimen containing ethionamide, 35% in patients who received a regimen containing PAS, and 44% in HIV-positive patients on ART (52).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567 · cited 2× · see citing works
“Patients found suffering from hypothyroidism were provided free treatment with levothyroxine according to international guidelines [9].”
BackgroundMethodGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053 · see citing works
High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho
Satti, H., Mafukidze, A., Jooste, P. L., McLaughlin, M., Farmer, P. E., & Seung, K. J. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0615 · Cited by 50 · see citing works
THE ANTI-THYROID ACTION OF PARA-AMINOSALICYLIC ACID
Macgregor, A., & Somner, A. R. (1954) · The Lancet · doi:10.1016/s0140-6736(54)92552-0 · Cited by 41 · cited 1× · see citing works
“In the event of drug intolerance or severe adverse reactions to kanamycin and cycloserine, paraaminosalicylate sodium (PAS) may be used as a substitute drug [3].”
BackgroundEthionamide-lnduced Goitrous Hypothyroidism
Drucker, D. J., EGGO, M. C., SALIT, I. E., & BURROW, G. N. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-6-837 · Cited by 40 · cited 1× · see citing works
“PAS and ethionamide are known to cause hypothyroidism [4].”
BackgroundAssociation between antiretrovirals and thyroid diseases: a cross-sectional study
Silva, G. A. R. D., Andrade, M. C. T., Sugui, D. D. A. S., Nunes, R. F., Pinto, J. F. D. C., Silva, W. D. A. E., Ferry, F. R. D. A., Azevedo, M. C. V. M. D., & Motta, R. N. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000023 · Cited by 37 · cited 1× · see citing works
“Antiretroviral drugs (stavudine, didanosine, and protease inhibitors) used for treatment of HIV can also cause hypothyroidism [5].”
BackgroundAndries, A., Isaakidis, P., Das, M., Khan, S., Paryani, R., Desai, C., Dalal, A., Mansoor, H., Verma, R., Fernandes, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078313 · Cited by 27 · cited 1× · see citing works
“According to studies carried out elsewhere, 54% – 69% of patients might develop hypothyroidism during treatment for MDR-TB [6]–[8].”
BackgroundPrevalence of hypothyroidism among MDR-TB patients in Botswana [Correspondence]
Modongo, C., & Zetola, N. M. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0403 · Cited by 23 · cited 1× · see citing works
“According to studies carried out elsewhere, 54% – 69% of patients might develop hypothyroidism during treatment for MDR-TB [6]–[8].”
BackgroundHypothyroidism in MDR-TB treatment – Rare occurrence but a major concern
Akshata, J. S., Swapna, R., Chakraborty, A., Somashekar, M., & Buggi, S. (2015) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2015.03.022 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552 · see citing works
Yang, T., Park, H. O., Jang, H. N., Yang, J. H., Kim, S. H., Moon, S. H., Byun, J. H., Lee, C. E., Kim, J. W., & Kang, D. H. (2017) · Medicine · doi:10.1097/md.0000000000007482 · Cited by 105 · see citing works
“Among the 17 patients that received regimens containing PAS, 6 (35%) developed hypothyroidism.([16]) Furin et al([9]) have reported a hypothyroidism incidence of approximately 10% in their study, while hypothyroidism was found in 2.”
BackgroundSafety implications of combined antiretroviral and anti-tuberculosis drugs
Cerrone, M., Bracchi, M., Wasserman, S. A., Pozniak, A., Meintjes, G., Cohen, K., & Wilkinson, R. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1694901 · Cited by 50 · see citing works
Endocrine and Metabolic Aspects of Tuberculosis
Vinnard, C., & Blumberg, E. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tnmi7-0035-2016 · Cited by 41 · see citing works
L-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · see citing works
Tola, H. H., Holakouie-Naieni, K., Lejisa, T., Mansournia, M. A., Yaseri, M., Tesfaye, E., & Mola, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218487 · Cited by 11 · see citing works
Sagili, K. D., Satyanarayana, S., Chadha, S. S., Wilson, N. C., Kumar, A. M. V., Moonan, P. K., Oeltmann, J. E., Chadha, V. K., Nagaraja, S. B., Ghosh, S., et al. (2018) · Global Health Action · doi:10.1080/16549716.2018.1445467 · Cited by 11 · see citing works
“A study in Bangalore reported that prevalence of hypothyroidism during MDR treatment was substantially greater when patients had routine serologic testing as compared to passive detection (23% vs 4%) [33].”
BackgroundHypothyroidism associated with therapy for multi‐drug‐resistant tuberculosis in Australia
Cheung, Y.-M. M., Van, K., Lan, L., Barmanray, R., Qian, S. Y., Shi, W. Y., Wong, J. L. A., Hamblin, P. S., Colman, P. G., Topliss, D. J., et al. (2018) · Internal Medicine Journal · doi:10.1111/imj.14085 · Cited by 11 · see citing works
Drug-induced hypothyroidism in tuberculosis
Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., Urteaga, L. A. C., Pecho‐Silva, S., Rodríguez-Hidalgo, L. A., & Concepción‐Zavaleta, M. J. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2307525 · Cited by 6 · see citing works
“%) of patients who develop antitubercular drug-induced hypothyroidism do so after 2 to 3 months of treatment [23,25,29].”
BackgroundThe Potential Interaction of Ethionamide-Thyroid Hormone Receptor Induces Hypothyroidism
Lesmana, R., Shidqi, F. R., Goenawan, H., Setiawan, I., Gondokesumo, M. E., Suhud, F., & Wathoni, N. (2021) · Pharmacognosy Journal · doi:10.5530/pj.2021.13.150 · Cited by 5 · see citing works
Varghese, V., Menon, K., & Green, S. R. (2018) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20182124 · Cited by 5 · see citing works
Endocrine and Metabolic Aspects of Tuberculosis
Vinnard, C., & Blumberg, E. A. (2017) · ASM Press eBooks · doi:10.1128/9781555819866.ch30 · Cited by 3 · see citing works
Yang, Y., & Huang, X. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09099-1 · Cited by 2 · see citing works
“Some medications, such ethionamide, prothionamide, and para-aminosalicylate sodium, can induce hypothyroidism during TB treatment [8].”
BackgroundEndocrine and Metabolic Manifestations of Tuberculosis
Patil, M. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.88 · Cited by 1 · see citing works
Hypothyroidism induced by antituberculosis drugs
Bacinschi, N., Vudu, L., Bacinschi-Gheorghiţă, S., & Bacinschi, A. (2023) · Bulletin of the Academy of Sciences of Moldova Medical Sciences · doi:10.52692/1857-0011.2022.3-74.40
Thyroid Profile of Childhood Tuberculosis Treated with Anti Tuberculosis Drug During Intensive Phase
Anam, M. S., Mahmudah, M., Cayami, F. K., Mexitalia, M., Sidhartani, M., Subagio, H. W., & Utari, A. (2022) · Journal of Biomedicine and Translational Research · doi:10.14710/jbtr.v8i3.15664
Matvyeyeva, S. L., Shevchenko, O. S., & Tudor, O. (2023) · Інфекційні хвороби · doi:10.11603/1681-2727.2023.4.14245
Владимировна, Т. Н., Stavitskaya, N. V., Smerdin, S., Плеханова, М. А., Vershinina, M. V., & Gordeev, A. A. (2024) · Tuberculosis and lung diseases · doi:10.58838/2075-1230-2024-102-6-128-134
Khan, H. A., Devi, U., Iqbal, M. F., & Aamir, A. (2025) · Oxford Medical Case Reports · doi:10.1093/omcr/omaf008
“Research from Karnataka, India indicated that approximately 23% of MDR-TB patients with accurate thyroid-stimulating hormone (TSH) readings develop hypothyroidism during anti-TB treatment [1].”
Yendapally, R., & Medina, J. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00752-1
- Authors
- Munivenkatappa, S., Anil, S., Naik, B., Volkmann, T., Sagili, K. D., Akshatha, J. S., Buggi, S., Sharada, M. A., Kulkarni, S., Chadha, V. K., & Moonan, P. K.
- Affiliations
- World Health Organization - India (IN)
- Centers for Disease Control and Prevention (US)
- International Union Against Tuberculosis and Lung Disease (US)
- National Tuberculosis Institute (IN)
- Corresponding author
- Munivenkatappa, Somashekar
- Moonan, Patrick K.
- Venue
- Journal of Tuberculosis Research
- Publisher
- Scientific Research Publishing, Inc.
- Published
- 2016
- Volume
- 04
- Issue
- 03
- Pages
- 105-110
- ISSN
- 2329-843X (ISSN-L)
- 2329-8448
- PMC
- PMC5007858
- OpenAlex
- W2514808739
- Cited by
- 20
- References
- 9
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 3
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Journal of Tuberculosis Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- Funders
- Global Fund to Fight AIDS, Tuberculosis and Malaria
- World Health Organization
- Ministry of Health and Family Welfare
- National Institutes of Health (CC999999)
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- drug-induced hypothyroidism, multidrug-resistant tuberculosis, tuberculosis treatment, ethionamide, thyroid-stimulating hormone, HIV coinfection, antiretroviral therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
